I have shared lots of information with you about the exciting new antibody therapy, elotuzumab.
The fact CURE Magazine and Reuters are running articles about it is a very good sign:
Promising early results from drug combo for advanced multiple myeloma
MAY 15, 2012 – CURE Magazine
NEW YORK (Reuters Health) – More than 80% of patients with advanced multiple myeloma responded to elotuzumab plus lenalidomide and low-dose dexamethasone in a phase I study.
“I am a great believer of combination therapy, and in order to have successful combinations, one needs agents that can be combined safely,” Dr. Sagar Lonial from Emory University, Atlanta, Georgia told Reuters Health in an email. “The safety and efficacy of the combination in our phase I study is quite striking, and with the activity of the combination, it represents a great new hope for patients.”
Elotuzumab is a humanized monoclonal immunoglobulin G1 antibody targeting CS1, a surface glycoprotein highly expressed on MM cells. Dr. Lonial and colleagues tested it in combination with lenalidomide and low-dose dexamethasone in 29 patients with refractory or relapsed MM…
You can more by CLICKING HERE.
Nothing new here–but it is impressive to read about how “All but one patient with no prior exposure to lenalidomide (21/22, 95%) achieved at least a partial response… Even among the 12 patients who were refractory to their most recent therapy, 10 (83%) achieved a partial response or better with the combination.”
Looks like elotuzumab helps make myeloma more susceptible to Revlimid therapy–and hopefully Velcade and others, too.
The first step toward breaking-down myeloma’s lethal ability to become drug resistant.
Feel good and keep smiling! Pat